T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response

T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response

The role of T cell receptor (TCR) signaling for adaptive immune responses is essential. The ability to respond to a broad spectrum of tumor antigens requires an adaptive selection of various TCR. So far, little is known about the role of TCR richness and clonality in the cellular immune response to...

Full description

Bibliographic Details
Main Authors:	Benjamin A. Kansy, Gulidanna Shayan, Hyun-Bae Jie, Sandra P. Gibson, Yu L. Lei, Sven Brandau, Stephan Lang, Nicole C Schmitt, Fei Ding, Yan Lin, Robert L. Ferris
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2018-11-01
Series:	OncoImmunology
Subjects:	tcr immunosequencing cetuximab egfr cytotoxic t cells head and neck cancer immunotherapy
Online Access:	http://dx.doi.org/10.1080/2162402X.2018.1494112

Similar Items

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines
by: Izabela N. F. Gomes, et al.
Published: (2022-01-01)

The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
by: Sapna Krishnamurthy, et al.
Published: (2022-05-01)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Miren Taberna, et al.
Published: (2019-05-01)

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
by: Giuliani Jacopo, et al.
Published: (2014-04-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
by: Schmitz Sandra, et al.
Published: (2015-03-01)

Cetuximab Concomitant with Second-Line Radiation Therapy in Patients with Locally Advanced Recurrent Squamous Cell Head and Neck Cancer
by: Muge Akmansu, et al.
Published: (2010-12-01)

Transgenic goats producing an improved version of cetuximab in milk
by: Götz Laible, et al.
Published: (2020-11-01)

Gold nanoparticles affect the antioxidant status in selected normal human cells
by: Daems N, et al.
Published: (2019-07-01)

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
by: Pierluigi Bonomo, et al.
Published: (2018-02-01)

Concurrent Radiotherapy with Carboplatin and Cetuximab for the Treatment of Medically Compromised Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
by: Kunal eSaigal, et al.
Published: (2014-06-01)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
by: Sadamoto Zenda, et al.
Published: (2019-01-01)

Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
by: Michael Pogorzelski, et al.
Published: (2021-05-01)

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
by: Mari Iida, et al.
Published: (2022-04-01)

Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab
by: Xuefeng Wang, et al.
Published: (2025-03-01)

Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
by: Avinash Khadela, et al.
Published: (2023-01-01)

Incidence and risk factors of hypomagnesemia in head and neck cancer patients treated with cetuximab
by: Tomohiro Enokida, et al.
Published: (2016-09-01)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
by: Juan A. Marín-Jiménez, et al.
Published: (2022-07-01)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

Stereotactic Body Radiotherapy as Primary Treatment for Elderly Patients with Medically Inoperable Head and Neck Cancer
by: John A. Vargo, et al.
Published: (2014-08-01)

Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study
by: Hui-Ching Wang, et al.
Published: (2020-09-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
by: Dahan Laetitia, et al.
Published: (2011-11-01)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
by: Tien-Hua Chen, et al.
Published: (2022-12-01)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
by: Olivia Leblanc, et al.
Published: (2020-02-01)

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
by: Ferris Robert L, et al.
Published: (2011-10-01)

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)

Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain
by: Ruth Alvarez Cabellos, et al.
Published: (2025-01-01)

Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx
by: Mindaugas Grybauskas, et al.
Published: (2014-01-01)

Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
by: Jacques Bernier
Published: (2011-12-01)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
by: Emmanuel Seront, et al.
Published: (2019-03-01)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
by: Tomohiro Enokida, et al.
Published: (2018-08-01)

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
by: Zhihao Lu, et al.
Published: (2022-05-01)

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
by: Elli Narvi, et al.
Published: (2018-11-01)

Chemotherapy with cetuximab in head and neck squamous cell carcinoma: immunological aspects and markers of treatment effectiveness in clinical practice
by: A. I. Stukan, et al.
Published: (2024-06-01)

Cetuximab Combined With Sonodynamic Therapy Achieves Dual-Modal Image Monitoring for the Treatment of EGFR-Sensitive Non-Small-Cell Lung Cancer
by: Guanhua Qiu, et al.
Published: (2022-02-01)

Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
by: Lang Y, et al.
Published: (2020-11-01)

Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT
by: Joël Guigay, et al.
Published: (2022-02-01)

Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen
by: Muh-Hwa Yang, et al.
Published: (2024-10-01)